MorphoSys AG And Merck Serono Enter Strategic Immuno-Oncology Collaboration
Martinsried / Munich, Germany, June 12, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Merck today announced that they have signed an agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints.
Help employers find you! Check out all the jobs and post your resume.